More than a third of medical device incidents involved a use error and more than half of all device recalls for design problems involve the user interface. The FDA has made medical device usability a key topic of concern and has issued guidance.
This event will bring together a mix of science, design and engineering professionals involved in medical device research and product development, regulatory, clinical, quality and marketing professionals with an interest in medical device usability to discuss the importance of usability in medical device design from software, hardware, human factors, clinical and regulatory perspectives.
If you would like to meet up with us there, please contact us.
Related CBSET Services:
- CBSET GLP Preclinical Services
- Localized/Targeted Drug Delivery
- Computational Modeling of Local Drug Delivery
- Cell-Based Therapies
Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings. Tzafriri AR, Garcia-Polite F, Li X, Keating J, Balaguer JM, Zani B, Bailey L, Markham P, Kiorpes TC, Carlyle W, Edelman ER. Journal of Controlled Release. Volume 274, 28 March 2018, Pages 102-108
Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosis. Abraham R. Tzafriri, Fernando Garcia-Polite, Brett Zani, James Stanley, Benny Muraj, Jennifer Knutson, Robert Kohler, Peter Markham, Alexander Nikanorov, Elazer R. Edelman. Journal of Controlled Release, Volume 264, 28 October 2017, Pages 203-210.
A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials: A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER. Biomaterials. 2016 Jul;93:71-82. doi: 10.1016/j.biomaterials.2016.03.044.